Related Experiment Videos
Recombinant immunotoxins for cancer therapy
U Brinkmann1, A Keppler-Hafkemeyer, P Hafkemeyer
1Epidauros Biotechnology, Pharmacogenetics Lab, Bernried, FRG, Germany. uli@epidauros.com
Abstract:
Recombinant immunotoxins consist of Fv regions of tumour-selective antibodies fused to toxins found in bacteria, plants or fungi. These toxins must be modified to remove normal-tissue binding sites but to retain all other functions of cytotoxicity. The recombinant antibody fragments target the modified toxin to cancer cells which are killed, either by direct inhibition of protein synthesis, or by concomitant induction of apoptosis. Cells that are not recognised by the antibody fragment because they do not carry the tumour antigen, are spared. Many factors influence the in vivo antitumour activity of recombinant immunotoxins. Among them are considerations of which types of cancer may be the best targets for immunotoxin therapy as well as tumour specificity of the antigen that is targeted by the recombinant antibody. Other relevant issues are the affinity of immunotoxins and their ability to enter and penetrate into tissues and tumours, which in turn is dependent on the size of the protein. A great deal of protein-engineering is required to stabilise the recombinant antibody moiety of immunotoxins, since stability of the molecules is crucial for good clinical efficacy. Excellent activity and specificity can be observed for many recombinant immunotoxins in in vitro assays using cultured cancer cells as well as in animal tumour models. Ongoing clinical trials provide examples where the promising preclinical data correlate with successful results in experimental cancer therapy.
Insights
Recombinant immunotoxins, engineered antibodies fused to modified toxins, selectively kill cancer cells by targeting tumor antigens. Protein engineering enhances their stability and efficacy, showing promise in preclinical and clinical cancer therapy.
Area of Science:
- Oncology
- Biotechnology
- Molecular Biology
Background:
- Recombinant immunotoxins combine tumor-targeting antibodies with cytotoxic toxins.
- Toxins are modified to eliminate normal tissue binding while retaining cancer cell killing ability.
- These agents induce cancer cell death via protein synthesis inhibition or apoptosis.
Purpose of the Study:
- To explore the development and application of recombinant immunotoxins in cancer therapy.
- To identify key factors influencing the in vivo antitumour activity of these agents.
- To assess the correlation between preclinical findings and clinical trial outcomes.
Main Methods:
- Engineering Fv antibody regions fused to modified bacterial, plant, or fungal toxins.
- Modifying toxins to remove normal tissue binding sites while preserving cytotoxicity.
- Utilizing in vitro assays with cultured cancer cells and in vivo studies with animal tumor models.
- Protein engineering to enhance the stability of the recombinant antibody moiety.
Main Results:
- Recombinant immunotoxins demonstrate specific targeting of cancer cells expressing tumor antigens.
- Effective cancer cell killing observed through direct protein synthesis inhibition or apoptosis induction.
- Preclinical studies show excellent activity and specificity in vitro and in animal models.
- Ongoing clinical trials indicate a correlation between promising preclinical data and successful experimental cancer therapy.
Conclusions:
- Recombinant immunotoxins offer a targeted approach to cancer therapy by sparing normal tissues.
- Factors such as antigen specificity, affinity, size, and protein stability are critical for clinical efficacy.
- The promising results from preclinical evaluations suggest significant potential for recombinant immunotoxins in clinical cancer treatment.